MINIREVIEW

You have free access to this content

LRRK2 in Parkinson’s disease: in vivo models and approaches for understanding pathogenic roles

  1. Zhenyu Yue

Article first published online: 5 OCT 2009

DOI: 10.1111/j.1742-4658.2009.07343.x

Issue

FEBS Journal

FEBS Journal

Volume 276, Issue 22, pages 6445–6454, November 2009

Additional Information

How to Cite

Yue, Z. (2009), LRRK2 in Parkinson’s disease: in vivo models and approaches for understanding pathogenic roles. FEBS Journal, 276: 6445–6454. doi: 10.1111/j.1742-4658.2009.07343.x

Author Information

  1. Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY, USA

*Z. Yue, Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY 10029, USA Fax: +1 212 241 3869 Tel: +1 212 241 3155 E-mail: zhenyu.yue@mssm.edu

Publication History

  1. Issue published online: 23 OCT 2009
  2. Article first published online: 5 OCT 2009
  3. (Received 30 May 2009, revised 30 July 2009, accepted 18 August 2009)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (216K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Erwan Bezard, Zhenyu Yue, Deniz Kirik, Maria Grazia Spillantini, Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies, Movement Disorders, 2013, 28, 1
    Direct Link:
  2. 2
    Heinz Steiner, LRRKing up the right trees? On figuring out the effects of mutant LRRK2 and other Parkinson's disease-related genes, Basal Ganglia, 2013, 3, 2, 73

    CrossRef

  3. 3
    Angela L. Shamchuk, Keith B. Tierney, Animal Models for the Study of Human Disease, 2013,

    CrossRef

  4. 4
    Zhenyu Yue, Genetic mouse models for understanding LRRK2 biology, pathology and pre-clinical application, Parkinsonism & Related Disorders, 2012, 18, S180

    CrossRef

  5. 5
    Laura Civiero, Luigi Bubacco, Human leucine-rich repeat kinase 1 and 2: intersecting or unrelated functions?, Biochemical Society Transactions, 2012, 40, 5, 1095

    CrossRef

  6. 6
    Zhenyu Yue, M. Lenard Lachenmayer, Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications, Movement Disorders, 2011, 26, 8
    Direct Link:
  7. 7
    Daniel C. Berwick, Kirsten Harvey, LRRK2 signaling pathways: the key to unlocking neurodegeneration?, Trends in Cell Biology, 2011, 21, 5, 257

    CrossRef

  8. 8
    Maria Trinidad Herrero, Javier Pagonabarraga, Gurutz Linazasoro, Neuroprotective Role of Dopamine Agonists, The Neurologist, 2011, 17, S54

    CrossRef

  9. 9
    Mathieu F. Bakhoum, George R. Jackson, Animal Models of Human Disease, 2011,

    CrossRef

  10. 10
    Won-Gi Seol, Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease, BMB Reports, 2010, 43, 4, 233

    CrossRef

  11. 11
    Jean-Marc Taymans, Mark R. Cookson, Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α-synuclein, and tau, BioEssays, 2010, 32, 3
    Direct Link:
View Full Article (HTML) Get PDF (216K)